Imfinzi® (durvalumab) – New indication
December 5, 2024, - AstraZeneca announced the FDA approval of Imfinzi (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT).
Top